August 16, 2016
Novocure Converts More Than 500 U.S. Patients to Second Generation Optune within Four Weeks of FDA Approval on July 13
The second generation device is less than half the weight and half the size of the first generation Optune System (Photo: Business Wire) August 16, 2016 07:00 AM Eastern Daylight Time ST. HELIER, Jersey–(BUSINESS WIRE)–Before starting treatment with Optune in October 2015,… Read More
learn more
August 8, 2016
Novocure to Present at Upcoming Investor Conferences
August 08, 2016 04:05 PM Eastern Daylight Time ST. HELIER, Jersey–(BUSINESS WIRE)–Novocure (NASDAQ: NVCR) announced today that it will present at three upcoming investor conferences in August and September. William Doyle, Novocure’s Executive Chairman, will present at the Wedbush PacGrow 2016 Healthcare Conference… Read More
learn more
July 28, 2016
Novocure Reports Second Quarter 2016 Financial Results and Provides Company Update
Continued growth in active patients with 891 active patients at June 30, 2016, an increase of 110 percent from second quarter 2015, and 12 percent from first quarter 2016 Second quarter 2016 reported revenues of $17.9 million, reflecting 174 percent growth versus second quarter 2015 and 37… Read More
learn more
July 28, 2016
Novocure to Host Research and Development Day on Dec. 12, 2016
July 28, 2016 06:25 AM Eastern Daylight Time ST. HELIER, Jersey–(BUSINESS WIRE)–Novocure (NASDAQ:NVCR) announced today that the company will hold a research and development day for analysts and investors on Monday, Dec. 12, 2016, from 1 to 4 p.m. EST in New York City. During the event, we… Read More
learn more
July 26, 2016
NCCN Guidelines Recommend Optune as a Standard Treatment Option for Newly Diagnosed Glioblastoma
Optune designated as category 2A treatment for newly diagnosed GBM, indicating uniform consensus that the intervention is appropriate July 26, 2016 09:46 AM Eastern Daylight Time ST. HELIER, Jersey–(BUSINESS WIRE)–Novocure (NASDAQ: NVCR) announced today that the National Comprehensive Cancer Network (NCCN) has recommended Optune as… Read More
learn more
July 13, 2016
Novocure Receives FDA Approval for Second Generation Optune System
Second generation Optune system is less than half the weight and size of first generation Optune system New system aims to make Optune therapy even easier for glioblastoma (GBM) patients Novocure’s new system aims to make Optune therapy even easier for… Read More
learn more
July 13, 2016
Novocure Receives FDA Approval for Second Generation Optune System
Second generation Optune system is less than half the weight and size of first generation Optune system New system aims to make Optune therapy even easier for glioblastoma (GBM) patients Novocure’s new system aims to make Optune therapy even easier for… Read More
learn more
June 30, 2016
Novocure to Report Second Quarter 2016 Financial Results
June 30, 2016 07:00 AM Eastern Daylight Time ST. HELIER, Jersey–(BUSINESS WIRE)–Novocure (NASDAQ: NVCR) announced today that it will report financial results for the second quarter 2016 on Thursday, July 28, 2016 at 6:30 a.m. EDT before the open of U.S.-based financial markets. Novocure management will host a… Read More
learn more
June 30, 2016
Novocure Announces $75 Million Drawdown under Its Term Loan Agreement through Pharmakon Advisors
Non-dilutive financing enhances financial strength June 30, 2016 04:00 PM Eastern Daylight Time ST. HELIER, Jersey–(BUSINESS WIRE)–Novocure (NASDAQ: NVCR) announced today that it has provided notice to draw the remaining $75 million under its existing term loan agreement with an investment fund managed by Pharmakon… Read More
learn more
June 30, 2016
Novocure Announces $75 Million Drawdown under Its Term Loan Agreement through Pharmakon Advisors
Non-dilutive financing enhances financial strength June 30, 2016 04:00 PM Eastern Daylight Time ST. HELIER, Jersey–(BUSINESS WIRE)–Novocure (NASDAQ: NVCR) announced today that it has provided notice to draw the remaining $75 million under its existing term loan agreement with an investment fund managed by Pharmakon… Read More
learn more
